TB500/BPC157 15mg Canada

Technical Specifications

Product Name: TB500/BPC157
Total Peptide Content: 15mg per vial
Components: TB-500 (Thymosin Beta-4 fragment) / BPC-157 (Pentadecapeptide)
Format: Lyophilized peptide blend
Purity Standard: ≥98% (individual components, batch dependent)
Research Classification: Investigational peptide blend – laboratory research use only

TB500/BPC157 15mg, Canada, is supplied as a lyophilized dual-peptide formulation intended exclusively for laboratory and analytical applications. Each vial contains 15 milligrams of synthetic peptide composed of TB-500 and BPC-157.

This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada.

Research Overview

TB500/BPC157 15mg Canada combines two peptides that have been studied individually in experimental and preclinical research environments. TB-500 is a synthetic analogue derived from a segment of thymosin beta-4, a naturally occurring protein involved in actin regulation. BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a gastric protein studied in cellular signalling research.

In the scientific literature, TB-500 has been examined in laboratory models that explore cytoskeletal organization, actin polymerization, and cellular migration. BPC-157 has been investigated in preclinical research settings, evaluating peptide-mediated signalling pathways and cellular response models.

The combined presentation of TB500/BPC157 15mg Canada reflects a research-oriented formulation used to facilitate comparative or concurrent evaluation of these two peptide systems under controlled laboratory conditions. Multi-peptide blends are occasionally examined in experimental contexts to observe signalling interactions or parallel pathway activation within in vitro or animal models.

All descriptions of biological pathways remain confined to investigational research findings and do not imply approved clinical application.

Mechanism Overview

TB500/BPC157 15mg Canada contains two structurally distinct peptides with different molecular targets in experimental systems.

TB-500 is a synthetic fragment modelled after thymosin beta-4. In laboratory studies, thymosin beta-4 has been shown to interact with G-actin and influence actin filament dynamics. TB-500 is evaluated in research models to assess its impact on cytoskeletal organization and cellular motility pathways.

BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein sequence originally identified in gastric tissue. Research involving BPC-157 has focused on modulation of the nitric oxide pathway, angiogenic signalling models, and cellular migration assays in controlled experimental systems.

When combined as TB500/BPC157 15mg Canada, these peptides are studied for their independent and potentially overlapping effects on cellular signalling, extracellular matrix interaction, and cytoskeletal processes in laboratory settings. Mechanistic discussions are based on preclinical research data and do not represent therapeutic mechanisms.

Clinical Development Context

Both TB-500 and BPC-157 have primarily been investigated in preclinical models, including cell culture studies and animal experiments. Published literature describes exploratory research examining peptide-mediated signalling in controlled environments.

Health Canada has not approved TB-500 or BPC-157 as a prescription medication or an over-the-counter product in peptide form. TB500/BPC157 15mg, supplied in Canada as a research-grade blend, reflects the investigational compound profiles described in scientific publications rather than authorized pharmaceutical preparations.

Clinical research involving these peptides remains limited, and current data are derived largely from laboratory-based studies.

Regulatory Status in Canada

TB500/BPC157 15mg Canada is classified as an investigational research peptide blend. Health Canada does not authorize it as a therapeutic drug, natural health product, or consumer health item.

The peptides within TB500/BPC157 15mg Canada are supplied exclusively for laboratory and analytical purposes. They are not intended for human or veterinary administration.

Handling, storage, and study of TB500/BPC157 15mg in Canada must comply with applicable federal and provincial Canadian regulations governing chemical and biological research materials. Research institutions are responsible for ensuring regulatory compliance.

Molecular and Structural Notes

TB-500 is a synthetic peptide fragment derived from the larger thymosin beta-4 protein. Its amino acid sequence is designed to replicate specific structural motifs studied in actin-binding research.

BPC-157 is a pentadecapeptide consisting of 15 amino acids. Its relatively low molecular weight and stable structure have made it a subject of interest in peptide signalling research.

TB500/BPC157 15mg Canada is typically characterized using analytical methods such as high-performance liquid chromatography (HPLC) and mass spectrometry to confirm the identity and purity of each peptide component before blending.

The lyophilized format supports peptide stability during storage when maintained under appropriate laboratory conditions.

Frequently Asked Questions

What is TB500/BPC157 15mg Canada composed of?
TB500/BPC157 15mg Canada contains a combined total of 15mg of TB-500 and BPC-157 peptides.

Are TB-500 and BPC-157 approved for medical use in Canada?
No. Health Canada authorizes neither peptide for therapeutic or consumer use in research-grade form.

What type of product is TB500/BPC157 15mg Canada?
It is an investigational dual-peptide blend intended solely for laboratory research.

Does TB500/BPC157 15mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the lyophilized peptide components.

Can TB500/BPC157 15mg Canada be used outside research settings?
No. It is intended exclusively for controlled laboratory and analytical applications.

Educational Disclaimer

TB500/BPC157 15mg Canada is an investigational peptide blend supplied solely for laboratory and analytical use. Health Canada does not approve it as a medication, therapeutic agent, or consumer product.

The information provided on this page is educational and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of TB500/BPC157 15mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.